All In Biotech

Drug Trial Radar · NCT06546800

SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER

SPECIAL INVESTIGATION FOR ABRYSVO INTRAMUSCULAR INJECTION -INVESTIGATION IN INDIVIDUALS AGED 60 YEARS OR OLDER-

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

1,100

Planned (sponsor's estimate)

Start

May 27, 2025

Primary completion

Oct 28, 2027

Study completion Oct 28, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 9, 2024

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This post-marketing study is a multicenter cohort study in individuals aged 60 years or older vaccinated with Abrysvo (RSV vaccine)designed to confirm the safety in individuals aged 60 years or older under actual clinical practice in Japan.

Conditions

  • Respiratory Syncytial Virus Infection

Interventions

  • RSVpreF vaccineBiological

    Injection in the muscle, 1 dose 0.5mL

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of individuals aged 60 years or older reporting Adverse Reactions for 28 days after vaccination.Time frame: From the day of vaccination up to 28 days after vaccination.
  2. Percentage of individuals aged 60 years or older reporting Serious Adverse Reactions from the day of vaccination up to 28 days after vaccination.Time frame: From the day of vaccination up to 28 days after vaccination.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pfizer

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.